Immunologic human renal allograft injury associates with an altered IL-10/TNF-α expression ratio in regulatory B cells

Journal of the American Society of Nephrology

Volumn 25, Issue 7, 2014, Pages 1575-1585

  Cherukuri, Aravind ^a   Rothstein, David M ^b   Clark, Brendan ^a   Carter, Clive R ^a   Davison, Adam ^d   Hernandez Fuentes, Maria ^c   Hewitt, Eric ^e   Salama, Alan D ^f   Baker, Richard J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; MEMORY CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL; ADULT; BIOSYNTHESIS; CHRONIC ALLOGRAFT REJECTION; FEMALE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TUMOR; MALE; METABOLISM; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RENAL FUNCTION DECLINE; RETROSPECTIVE STUDY;

CHRONIC ALLOGRAFT REJECTION; IMMUNOLOGY; RENAL FUNCTION DECLINE;

ADULT; B-LYMPHOCYTES, REGULATORY; FEMALE; GRAFT REJECTION; HUMANS; INTERLEUKIN-10; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84907217845     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013080837     Document Type: Article

References (40)

1. Janeway CA Jr, Ron J, Katz ME: The B cell is the initiating antigen-presenting cell in peripheral lymph nodes. J Immunol 138: 1051-1055, 1987
2. ShlomchikMJ, Craft JE, Mamula MJ: FromT to B and back again: Positive feedback in systemic autoimmune disease. Nat Rev Immunol 1: 147-153, 2001
3. Ron Y, Sprent J: T cell priming in vivo: A major role for B cells in presenting antigen to T cells in lymph nodes. J Immunol 138: 2848-2856, 1987
4. Yanaba K, Bouaziz JD, Matsushita T, Magro CM, St Clair EW, Tedder TF: B-lymphocyte contributions to human autoimmune disease. Immunol Rev 223: 284-299, 2008
5. Lund FE, Randall TD: Effector and regulatory B cells: Modulators of CD4+ T cell immunity. Nat Rev Immunol 10: 236-247, 2010
6. Barr TA, GrayM, Gray D: B cells: Programmers of CD4 T cell responses. Infect Disord Drug Targets 12: 222-231, 2012
7. Shlomchik MJ: Activating systemic autoimmunity: B's, T's, and tolls. Curr Opin Immunol 21: 626-633, 2009
8. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM, Johnson LL, Swain SL, Lund FE: Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1: 475-482, 2000
9. Lund FE: Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol 20: 332-338, 2008
10. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK: Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 186: 1749-1756, 1997
11. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK: Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 16: 219-230, 2002
12. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM: B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3: 944-950, 2002
13. Mauri C, Gray D, Mushtaq N, Londei M: Prevention of arthritis by interleukin 10-producing B cells. J ExpMed 197: 489-501, 2003
14. Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H, Chalasani G, Sayegh MH, Najafian N, Rothstein DM: Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest 121: 3645-3656, 2011
15. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF: A regulatory B cell subsetwith a uniqueCD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650, 2008
16. Hussain S, Delovitch TL: Intravenous transfusion of BCR-activated B cells protects NOD mice from type 1 diabetes in an IL-10-dependent manner. J Immunol 179: 7225-7232, 2007
17. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C: CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 32: 129-140, 2010
18. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF: Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117: 530-541, 2011
19. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Wei C, Looney RJ, Sanz I, Anolik JH: Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol 182: 5982-5993, 2009
20. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE: Identification and characterization of circulating human transitional B cells. Blood 105: 4390-4398, 2005
21. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C: Novel suppressive function of transitional 2 B cells in experimental arthritis. J Immunol 178: 7868-7878, 2007
22. Gray M, Miles K, Salter D, Gray D, Savill J: Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells. Proc Natl Acad Sci U S A 104: 14080-14085, 2007
23. Mann MK, Maresz K, Shriver LP, Tan Y, Dittel BN: B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis. J Immunol 178: 3447-3456, 2007
24. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF: Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 118: 3420-3430, 2008
25. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK: Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol 12: 597-605, 2000
26. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A: Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178: 6092-6099, 2007
27. Correale J, Farez M, Razzitte G: Helminth infections associated with multiple sclerosis induce regulatory Bcells.AnnNeurol 64: 187-199, 2008
28. Sho M, Yamada A, Najafian N, Salama AD, Harada H, Sandner SE, Sanchez-Fueyo A, Zheng XX, Strom TB, Sayegh MH: Physiological mechanisms of regulating alloimmunity: Cytokines, CTLA-4, CD25+ cells, and the alloreactive T cell clone size. J Immunol 169: 3744-3751, 2002
29. Loupy A, Lefaucheur C, Vernerey D, Prugger C, van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X: Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 369: 1215-1226, 2013
30. Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, Goldberg A, Birk PE, Rush DN, Nickerson PW: Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 12: 1157-1167, 2012
31. WojciechowskiW, Harris DP, Sprague F, Mousseau B, Makris M, Kusser K, Honjo T, Mohrs K, MohrsM, Randall T, Lund FE: Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. Immunity 30: 421-433, 2009
32. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH: Abnormal Bcell cytokine responses a trigger of T-cell-mediated disease inMS? Ann Neurol 67: 452-461, 2010
33. Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, Burlingham WJ, Marks WH, Sanz I, Lechler RI, Hernandez-Fuentes MP, Turka LA, Seyfert-Margolis VL; Immune Tolerance Network ST507 StudyGroup: Identification of a B cell signature associatedwith renal transplant tolerance in humans. J Clin Invest 120: 1836-1847, 2010
34. Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, Chapman S, Craciun L, Sergeant R, Brouard S, Rovis F, Jimenez E, Ballow A, Giral M, Rebollo-Mesa I, Le Moine A, Braudeau C, Hilton R, Gerstmayer B, Bourcier K, Sharif A, Krajewska M, Lord GM, Roberts I, Goldman M, Wood KJ, Newell K, Seyfert-Margolis V, Warrens AN, Janssen U, Volk HD, Soulillou JP, Hernandez-Fuentes MP, Lechler RI: Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 120: 1848-1861, 2010
35. Cherukuri A, Salama AD, Carter C, Smalle N, McCurtin R, Hewitt EW, Hernandez-Fuentes M, Clark B, Baker RJ: An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. Am J Transplant 12: 919- 931, 2012
36. Brouard S, Renaudin K, Soulillou JP: Revisiting the natural history of IF/ TA in renal transplantation. Am J Transplant 11: 647-649, 2011
37. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ: Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90: 68-74, 2010
38. Kieran N, Wang X, Perkins J, Davis C, Kendrick E, Bakthavatsalam R, Dunbar N, Warner P, Nelson K, Smith KD, Nicosia RF, Alpers CE, Leca N, Kowalewska J: Combination of peritubular c4d and transplant glomerulopathy predicts late renal allograft failure. J Am SocNephrol 20: 2260-2268, 2009
39. Dudley C, Pohanka E, Riad H, Dedochova J, Wijngaard P, Sutter C, Silva HT Jr; Mycophenolate Mofetil Creeping Creatinine Study Group: Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: The "creeping creatinine" study. Transplantation 79: 466-475, 2005
40. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Cendales L, Demetris AJ, Drachenberg CB, Farver CF, Rodriguez ER, Wallace WD, Glotz D; Banff Meeting Report Writing Committee: Banff 2011 meeting report: New concepts in antibody-mediated rejection. Am J Transplant 12: 563-570, 2012